Lipid Mediators: Advancements and Approaches - The Lipid Mediators Conference: Recent Advances and Clinical Approaches will be held September 7-11, 2025 at the Grand Hotel Malahide, Dublin, Ireland. This conference will address current research, and emerging concepts related to lysophospholipids, particularly sphingosine 1-phosphate (S1P) and lysophosphatidic acid (LPA) and their roles in health and disease. We have broadened the scope of the meeting and included ceramide (Cer) and specialized pro-resolving mediators (SPM), with a key role in inflammation. S1P, LPA and SPM are signaling lipids activating different G protein-coupled receptors, respectively, while ceramides bind to intracellular target proteins to regulate cell biology. These biological interactions control vital functions in the cardiovascular system, the immune system and the nervous system. These lipids are important in pulmonary fibrosis, atherosclerosis, cancer, autoimmunity, and other disease states, and the field is growing exponentially. Receptors as well as intracellular targets and enzymes regulating lysophospholipid metabolism and signaling have been shown to function as potential therapeutic targets to diagnose, prevent or treat disease. The conference will emphasize the translation of this work into clinical practice and highlight the research advances being made at a rapid pace by many new investigators in this field. The meeting provides a unique and invaluable forum for scientists from diverse disciplines to meet and discuss their latest research findings. The conference aims are to 1) provide intellectual exchange between scientists and trainees from multiple disciplines engaged in lysophospholipid, Cer and SPM research; 2) encourage and facilitate active discussion between early career and new investigators and established scientists via interactive career workshops and multiple opportunities for networking/collaboration; and 3) provide a platform to promote the scientific discussion among all participants. The conference will allow diverse early career and established investigators to communicate late-breaking research results and promote future interactions aligned with developing therapies for diseases in which lysophospholipids, Cer and SPM play a predominant role. The conference site in Ireland will facilitate maximum participation of European scientists, and scientist from all over the world, including USA, China, Australia, Japan and others to promote productive interactions focusing on the translational implications of lysophospholipids, Cer and SPM.
